INO

COVID-19 Vaccine

COVID-19

Stage (next event)

Expected Date

Phase 2/3 Initiation

TBD

Catalyst Info & Data Links

Mechanism of Action

MECHANISM OF ACTION

  • INO-4800 is a plasmid DNA vaccine that encode the SARS-CoV-2 spike protein. 

  • The advantages of INOVIO’s DNA medicine platform are how fast DNA medicines can be designed and manufactured; the stability of the products, which do not require freezing in storage and transport; and the robust immune response and tolerability that have been demonstrated in clinical trials.

  • With more than 2,000 patients receiving INOVIO DNA medicines in more than 7,000 applications across a range of clinical trials, INOVIO has a strong track record of rapidly generating DNA medicine candidates to meet urgent health needs.

Updated by MV

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

FDA Decision on Heron's Non-Opioid Pain Med Imminent

SUPN Reports Mixed Results in ADHD

Amp Up July 2018

ASCO 2018 Amp Noteworthy Abstracts

AACR 2018 Amp Up

Cidara Therapeutics: An Attractive Price For A Niche Opportunity With A High Probability Of Success

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon